round button
Leave a message

アジア太平洋地域の消化不良治療薬市場 – 業界動向と2030年までの予測

Request for TOC TOC のリクエスト Speak to Analyst アナリストに相談する Buy Now今すぐ購入 Inquire Before Buying 事前に問い合わせる Free Sample Report 無料サンプルレポート

アジア太平洋地域の消化不良治療薬市場 – 業界動向と2030年までの予測

  • Pharmaceutical
  • Published Report
  • May 2023
  • Asia-Pacific
  • 350 ページ
  • テーブル数: 506
  • 図の数: 52

アジア太平洋地域の消化不良治療薬市場

Market Size in USD Billion

CAGR :  % Diagram

Diagram 予測期間
2024 –2030
Diagram 市場規模(基準年)
USD MILLION
Diagram Market Size (Forecast Year)
USD MILLION
Diagram CAGR
%
Diagram 主要市場プレーヤー
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

アジア太平洋地域の消化不良薬市場 - タイプ別(有機性消化不良、非潰瘍性消化不良、薬剤誘発性消化不良、その他)、治療タイプ(投薬および手術)、薬の種類(ブランドおよびジェネリック)、処方(処方薬なしおよび処方薬)、投与経路(経口および注射)、性別(男性および女性)、エンドユーザー(病院、診療所、在宅ケア環境、専門診療所、外来手術センター、学術および政府研究機関、その他)、流通チャネル(直接入札および小売販売) - 2030年までの業界動向および予測。

アジア太平洋地域の消化不良治療薬市場

アジア太平洋地域の消化不良治療薬市場の分析と洞察

アジア太平洋地域の消化不良薬市場は、消化不良の罹患率の増加と不健康なライフスタイルの採用の増加により、予測期間中に成長すると予想されています。市場は、代謝障害の罹患率の増加にも影響されています。しかし、アジア太平洋地域の消化不良薬市場は、消化不良に使用される薬の副作用の可能性と、自然療法やハーブ療法の好みの高まりによって阻害されると予想されています。高齢化人口の増加と医薬品の承認の増加は、市場成長の機会として機能すると予想されています。しかし、厳しい規制と国民の間での消化不良に対する認識の欠如は、市場成長の課題になると予想されています。 

アジア太平洋地域の消化不良治療薬市場アジア太平洋地域の消化不良治療薬市場

データブリッジマーケットリサーチは、アジア太平洋地域の消化不良薬市場は2023年から2030年の予測期間中に6.1%のCAGRで成長すると予測していると分析しています。

レポートメトリック

詳細

予測期間

2023年から2030年

基準年

2022

歴史的な年

2021 (2015 - 2020 にカスタマイズ可能)

定量単位

売上高は千ドル、販売数量はユニット、価格は米ドル

対象セグメント

タイプ(器質性消化不良、非潰瘍性消化不良、薬剤誘発性消化不良、その他)、治療タイプ(薬物療法および手術)、薬剤タイプ(ブランド薬およびジェネリック薬)、処方(処方薬なしおよび処方薬)、投与経路(経口および注射)、性別(男性および女性)、エンドユーザー(病院、診療所、在宅ケア施設、専門診療所、外来手術センター、学術および政府研究機関、その他)、流通チャネル(直接入札および小売販売)

対象国

日本、中国、オーストラリア、インド、韓国、シンガポール、インドネシア、タイ、マレーシア、フィリピン、ニュージーランド、ベトナム、台湾、その他アジア太平洋地域

対象となる市場プレーヤー

バイエルAG、カディラ・ファーマシューティカルズ、サノフィ、ルピン、アボット、ペリゴ・カンパニー、アストラゼネカ、プロクター・アンド・ギャンブル、レキットベンキーザーなど

市場の定義

消化不良は、一般的に消化不良として知られ、食後に腹部に感じる痛みや不快感です。これは通常、GERD(胃食道逆流症)、胆嚢、潰瘍性疾患などの基礎疾患の兆候です。消化不良の治療は、原因と重症度によって異なります。基礎疾患を治療するか、薬を変更すると、消化不良が軽減されます。消化不良は、「器質性」と「機能性消化不良」(FD)の 2 つの主なカテゴリに分けられます。消化不良の器質性原因は、消化性潰瘍、胃食道逆流症、胃がんまたは食道がん、膵臓または胆道疾患、食物または薬物に対する不耐性、およびその他の感染症または全身性疾患です。機能性消化不良(ディスペプシーア)は、明らかな原因がない胃の不調の症状が繰り返し起こることを指す用語です。機能性消化不良は非潰瘍性消化不良とも呼ばれます。

アジア太平洋地域の消化不良治療薬市場の動向

このセクションでは、市場の推進要因、利点、機会、制約、課題について理解します。これらについては、以下で詳しく説明します。

ドライバー

  • 消化不良の有病率の増加

消化不良は、一般的に消化不良として知られ、アジア太平洋地域の何百万人もの人々を悩ませている胃腸障害です。上腹部に不快感、痛み、満腹感または膨張感を引き起こす症状です。消化不良は、食べるのが早すぎる、辛い食べ物や脂っこい食べ物を摂取する、薬の副作用など、さまざまな要因によって引き起こされる可能性があります。

消化不良の罹患率の増加は、消化不良薬市場の成長を促す主な要因の 1 つです。消化不良の発生率の上昇は、ライフスタイル、食習慣の変化、人口の高齢化など、いくつかの要因に起因しています。年齢を重ねるにつれて、消化不良などの消化器系の問題にかかりやすくなります。高齢者の数が増えるにつれて、消化不良薬の需要が高まっています。

さらに、過敏性腸症候群、胃不全麻痺、胃炎、消化性潰瘍などのさまざまな消化器疾患も、前述の疾患の罹患率の増加により、消化不良を引き起こします。したがって、消化不良および消化不良を引き起こすその他の消化器疾患の罹患率の増加は、市場の成長の原動力として機能すると予想されます。消化不良の症状を緩和し、消化不良を治療するための消化不良薬の使用は、患者の転帰を改善し、消化不良の負担を軽減する可能性があります。したがって、消化不良の罹患率の増加は、人口の間で消化不良の発生率と罹患率を増加させるため、世界中で消化不良薬の需要を促進しています。

  • 不健康なライフスタイルの採用の増加

近年、不健康なライフスタイルの採用が増加しており、これが消化不良の有病率の増加につながっています。加工食品を多く摂取する食生活、運動不足、過度のアルコール摂取など、不健康なライフスタイルの選択はすべて消化不良の一因となります。

その結果、人々は症状の緩和を求め、消化不良薬の需要もそれに応じて増加しました。消化不良薬市場では、プロトンポンプ阻害薬、H2受容体拮抗薬、制酸剤など、さまざまな医薬品でこの需要に応えてきました。

不健康なライフスタイルの採用が増えている原因としては、食習慣の変化、ストレスの増加、座りがちなライフスタイルなど、いくつかの要因が挙げられます。現代の生活は、長時間労働、ストレスの多さ、ファストフードやその他の不健康な選択肢への容易なアクセスが特徴です。これらの要因は、消化不良や胃食道逆流症 (GERD) などの関連疾患の一因となる可能性があります。

結論として、消化不良は、不健康なライフスタイルの選択など、さまざまな要因によって引き起こされる一般的な症状です。不健康なライフスタイルの採用の増加は、消化不良の有病率の増加に寄与しており、効果的な消化不良薬の需要もそれに応じて増加しており、市場の成長の原動力として機能することが期待されています。

機会

  • 高齢化人口の増加

推計によると、65歳以上の人口は2050年までに15億人に達すると予想されており、これは世界の人口が急速に高齢化していることを示しています。加齢とともに慢性的な健康状態になるリスクが高まります。これには、加齢の結果として起こる消化不良などの消化器疾患が含まれます。

人口の増加と高齢化により、消化不良薬市場は大きな拡大のチャンスを迎えています。消化器系の問題を抱える人が増えているため、症状の重症度を軽減し、全体的な生活の質を高める効果的な治療法に対するニーズが高まっています。

さらに、消化不良の治療は、高齢化社会のニーズに合わせて調整する必要があるかもしれません。高齢者は複数の慢性疾患を抱え、同時に複数の薬を服用している可能性があり、そのどちらも、薬物相互作用や副作用の可能性を高める可能性があります。その結果、高齢者に投与してもリスクがなく効果的な消化不良薬が求められています。また、高齢化に伴い、人々は体力と免疫力も低下し、消化不良を含むいくつかの胃腸関連疾患の罹患率が高まります。

したがって、消化不良とその症状を引き起こす高齢化人口の増加と、予防医療に対する人々の選好は、消化不良薬市場の成長の機会として機能すると予想されます。

抑制/挑戦

  • 国民の間で消化不良に対する認識が不足している

スキル不足はすでに国中に影響を与えており、歯科治療を6か月以上待たされる人が増えています。新興国や発展途上国では、技術の進歩、基本的なインフラ、その他いくつかの要因により、消化不良治療薬の分野で熟練した専門家が不足しています。

熟練した専門家が不足している理由の 1 つは、歯科専門家になるために必要な厳格な教育と訓練、および競争の激しい就職市場です。さらに、熟練した歯科医には、消化不良薬システムなどの高度な技術システムを運用および実行するための口腔ケアへのアクセスを維持および向上させるために、正式な訓練を受けた、資格のある歯科助手がさらに必要です。

新興国には、新しいテクノロジーを効果的に運用できない熟練した専門家が不足しています。これらの国々では、市場における技術主導の進歩の開始が遅れているため、新しいテクノロジーの出現に対する市場での課題が生じる可能性があります。

最近の動向

  • 2023年4月、サノフィはProvention Bio, Inc.の買収を完了したことを発表しました。この買収により、同社は総合医療事業の拡大に貢献しました。
  • 2022年7月、ANI Pharmaceuticals, Inc.は、非上場バイオ医薬品会社であるOakrum Pharma, LLCから4件の簡略新薬申請(ANDA)を購入すると発表しました。

アジア太平洋地域の消化不良治療薬市場のセグメンテーション

アジア太平洋地域の消化不良薬市場は、タイプ、治療タイプ、薬の種類、処方、投与経路、性別、エンドユーザー、流通チャネルに分類されています。セグメント間の成長は、ニッチな成長分野と市場へのアプローチ戦略を分析し、コアアプリケーション領域とターゲット市場の違いを判断するのに役立ちます。

タイプ

  • 非潰瘍性消化不良
  •  有機性消化不良
  •  薬剤誘発性消化不良
  •  その他

タイプに基づいて、アジア太平洋地域の消化不良薬市場は、有機性消化不良、非潰瘍性消化不良、薬剤誘発性消化不良、その他に分類されます。

治療の種類

  • 手術

治療の種類に基づいて、アジア太平洋地域の消化不良治療薬市場は薬物療法と外科手術に分類されます。

薬剤の種類

  • ブランド
  • ジェネリック

薬の種類に基づいて、アジア太平洋地域の消化不良薬市場はジェネリックとブランドに分類されます。

処方箋

  • 処方薬なし
  • 処方薬

処方に基づいて、アジア太平洋地域の消化不良薬市場は、処方箋なしの薬と処方薬に分類されます。

投与経路

  • オーラル
  • 注射可能

投与経路に基づいて、アジア太平洋地域の消化不良薬市場は経口薬と注射薬に分類されます。

性別

  • 女性

性別に基づいて、アジア太平洋地域の消化不良薬市場は男性と女性に区分されます。

エンドユーザー

  • 病院
  • クリニック
  • ホームケア設定
  • 専門クリニック
  • 外来センター
  • 学術機関および政府研究機関
  • その他

エンドユーザーに基づいて、アジア太平洋地域の消化不良薬市場は、病院、診療所、在宅ケア施設、専門診療所、外来手術センター、学術および政府研究機関、その他に分類されます。

流通チャネル

  • 直接入札
  • 小売販売

流通チャネルに基づいて、アジア太平洋地域の消化不良薬市場は、直接入札と小売販売に分類されます。

消化不良薬市場

アジア太平洋地域の消化不良治療薬市場の地域分析/洞察

アジア太平洋地域の消化不良薬市場を分析し、種類、治療の種類、薬の種類、処方、投与経路、性別、エンドユーザー、流通チャネルに基づいて市場規模の洞察と傾向を提供します。

この市場レポートで取り上げられている国は、日本、中国、オーストラリア、インド、韓国、シンガポール、インドネシア、タイ、マレーシア、フィリピン、ニュージーランド、ベトナム、台湾、およびその他のアジア太平洋諸国です。

日本国内での製品承認数の増加により、アジア太平洋地域の消化不良薬市場は日本が独占すると予想されています。

レポートの国別セクションでは、市場の現在および将来の動向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。下流および上流のバリュー チェーン分析、技術動向、ポーターの 5 つの力の分析、ケース スタディなどのデータ ポイントは、個々の国の市場シナリオを予測するために使用される指標の一部です。また、国別データの予測分析を提供する際には、アジア太平洋ブランドの存在と可用性、地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、国内関税と貿易ルートの影響も考慮されています。

競争環境とアジア太平洋地域の消化不良治療薬市場シェア分析

アジア太平洋の消化不良薬市場の競争状況は、競合他社の詳細を提供します。会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、アジア太平洋でのプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などの詳細が含まれます。上記のデータ ポイントは、市場に対する会社の重点にのみ関連しています。

市場で活動している主要な市場プレーヤーとしては、バイエルAG、カディラ・ファーマシューティカルズ、サノフィ、ルピン、アボット、ペリゴ・カンパニー、アストラゼネカ、プロクター・アンド・ギャンブル、レキットベンキーザーなどが挙げられます。


SKU-

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

  • インタラクティブなデータ分析ダッシュボード
  • 成長の可能性が高い機会のための企業分析ダッシュボード
  • カスタマイズとクエリのためのリサーチアナリストアクセス
  • インタラクティブなダッシュボードによる競合分析
  • 最新ニュース、更新情報、トレンド分析
  • 包括的な競合追跡のためのベンチマーク分析のパワーを活用
デモのリクエスト

目次

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE ASIA-PACIFIC DYSPEPSIA DRUG MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 MARKET END-USER COVERAGE GRID

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

5 EPIDEMIOLOGY

6 PROBLEMS IN THE MANAGEMENT OF DYSPEPSIA

7 INDUSTRY INSIGHTS:

8 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, REGULATION

9 MARKET OVERVIEW

9.1 DRIVERS

9.1.1 INCREASING PREVALENCE OF DYSPEPSIA

9.1.2 RISE IN THE ADOPTION OF UNHEALTHY LIFESTYLE

9.1.3 INCREASE IN THE PREVALENCE OF METABOLIC DISORDERS

9.2 RESTRAINTS

9.2.1 POSSIBLE SIDE EFFECTS OF THE DRUGS USED FOR DYSPEPSIA

9.2.2 INCREASING PREFERENCE FOR NATURAL AND HERBAL REMEDIES

9.3 OPPORTUNITIES

9.3.1 GROWING AGING POPULATION

9.3.2 RISE IN THE DRUG APPROVAL

9.4 CHALLENGES

9.4.1 LACK OF AWARENESS ABOUT DYSPEPSIA AMONG THE POPULATION

9.4.2 STRINGENT REGULATIONS

10 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY TYPE

10.1 OVERVIEW

10.2 NON-ULCER DYSPEPSIA

10.3 ORGANIC DYSPEPSIA

10.4 DRUG INDUCED DYSPEPSIA

10.5 OTHERS

11 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE

11.1 OVERVIEW

11.2 MEDICATION

11.2.1 DRUGS

11.2.1.1 ANTACIDS

11.2.1.1.1 PROTON PUMP INHIBITORS (PPI’S)

11.2.1.1.1.1 OMEPRAZOLE

11.2.1.1.1.2 LANSOPRAZOLE

11.2.1.1.1.3 ESOMEPRAZOLE

11.2.1.1.1.4 OTHERS

11.2.1.1.2 H2 BLOCKERS

11.2.1.1.2.1 CIMETIDINE

11.2.1.1.2.2 FAMOTIDINE

11.2.1.1.2.3 NIZATIDINE

11.2.1.1.2.4 RANITIDINE

11.2.1.1.2.5 OTHERS

11.2.1.2 GASTRIC PROKINETIC GENDERNTS

11.2.1.2.1 MOSAPRIDE CITRATE

11.2.1.2.2 METOCLOPRAMIDE

11.2.1.2.3 CISAPRIDE

11.2.1.2.4 ITOPRIDE HYDROCHLORIDE

11.2.1.2.5 DOMPERIDONE

11.2.1.2.6 OTHERS

11.2.1.3 ANTIBIOTICS

11.2.1.3.1 REFAXIMIN

11.2.1.3.2 AMOXICILLIN

11.2.1.3.3 CLARITHROMYCIN

11.2.1.3.4 METRONIDAZOLE

11.2.1.3.5 LEVOFLOXACIN

11.2.1.3.6 TETRACYCLINE

11.2.1.3.7 OTHERS

11.2.1.4 OTHERS

11.2.2 NON- DRUGS

11.2.2.1 PROBIOTICS

11.2.2.1.1 LACTOBACILLUS

11.2.2.1.2 BIFIDOBACTERIUM

11.2.2.1.3 BACILLUS

11.2.2.1.4 STREPTOCOCCUS

11.2.2.1.5 OTHERS

11.2.2.2 PREBIOTICS

11.3 SURGERY

12 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY DRUG TYPE

12.1 OVERVIEW

12.2 GENERIC

12.3 BRANDED

13 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY PRESCRIPTION

13.1 OVERVIEW

13.2 WITHOUT PRESCRIPTION DRUGS

13.3 PRESCRIPTION DRUGS

14 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION

14.1 OVERVIEW

14.2 ORAL

14.2.1 TABLETS

14.2.2 CAPSULES

14.3 INJECTABLE

15 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY GENDER

15.1 OVERVIEW

15.2 FEMALE

15.2.1 30-50 YEARS

15.2.2 MORE THAN 50 YEARS

15.2.3 AGE LESS THAN 30

15.3 MALE

15.3.1 30-50 YEARS

15.3.2 MORE THAN 50 YEARS

15.3.3 AGE LESS THAN 30

16 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY END USER

16.1 OVERVIEW

16.2 HOSPITALS

16.2.1 TYPE

16.2.1.1 PUBLIC

16.2.1.2 PRIVATE

16.2.2 TIER

16.2.2.1 TIER 3

16.2.2.2 TIER 2

16.2.2.3 TEIR 1

16.3 CLINICS

16.4 HOMECARE SETTINGS

16.5 SPECIALTY CLINICS

16.6 AMBULATORY CENTERS

16.7 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES

16.8 OTHERS

17 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL

17.1 OVERVIEW

17.2 RETAIL SALES

17.2.1 REATIL PHARMACY

17.2.2 HOSPITAL PHARMACY

17.2.3 ONLINE PHARMACY

17.3 DIRECT TENDER

18 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY REGION

18.1 ASIA-PACIFIC

18.1.1 JAPAN

18.1.2 CHINA

18.1.3 SOUTH KOREA

18.1.4 INDIA

18.1.5 AUSTRALIA

18.1.6 NEW ZEALAND

18.1.7 SINGAPORE

18.1.8 THAILAND

18.1.9 INDONESIA

18.1.10 MALAYSIA

18.1.11 PHILIPPINES

18.1.12 VIETNAM

18.1.13 TAIWAN

18.1.14 REST OF ASIA-PACIFIC

19 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, COMPANY LANDSCAPE

19.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

20 SWOT ANALYSIS

21 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, COMPANY PROFILINGS

21.1 SANOFI

21.1.1 COMPANY SNAPSHOT

21.1.2 REVENUE ANALYSIS

21.1.3 COMPANY SHARE ANALYSIS

21.1.4 PRODUCT PORTFOLIO

21.1.5 RECENT DEVELOPMENT

21.2 LUPIN

21.2.1 COMPANY SNAPSHOT

21.2.2 REVENUE ANALYSIS

21.2.3 COMPANY SHARE ANALYSIS

21.2.4 PRODUCT PORTFOLIO

21.2.5 RECENT DEVELOPMENTS

21.3 MANKIND PHARMA

21.3.1 COMPANY SNAPSHOT

21.3.2 REVENUE ANALYSIS

21.3.3 COMPANY SHARE ANALYSIS

21.3.4 PRODUCT PORTFOLIO

21.3.5 RECENT DEVELOPMENT

21.4 ASTRAZENECA

21.4.1 COMPANY SNAPSHOT

21.4.2 REVENUE ANALYSIS

21.4.3 COMPANY SHARE ANALYSIS

21.4.4 PRODUCT PORTFOLIO

21.4.5 RECENT DEVELOPMENT

21.5 BAYER AG

21.5.1 COMPANY SNAPSHOT

21.5.2 REVENUE ANALYSIS

21.5.3 COMPANY SHARE ANALYSIS

21.5.4 PRODUCT PORTFOLIO

21.5.5 RECENT DEVELOPMENT

21.6 ABBOTT

21.6.1 COMPANY SNAPSHOT

21.6.2 REVENUE ANALYSIS

21.6.3 PRODUCT PORTFOLIO

21.6.4 RECENT DEVELOPMENT

21.7 ANI PHARMACEUTICALS, INC.

21.7.1 COMPANY SNAPSHOT

21.7.2 REVENUE ANALYSIS

21.7.3 PRODUCT PORTFOLIO

21.7.4 RECENT DEVELOPMENT

21.8 AOSAIKANG PHARMACEUTICAL CO., LTD.

21.8.1 COMPANY SNAPSHOT

21.8.2 REVENUE ANALYSIS

21.8.3 PRODUCT PORTFOLIO

21.8.4 RECENT DEVELOPMENT

21.9 ASTERISK LABORATORIES (I) PVT. LTD

21.9.1 COMPANY SNAPSHOT

21.9.2 PRODUCT PORTFOLIO

21.9.3 RECENT DEVELOPMENT

21.1 CADILA PHARMACEUTICALS

21.10.1 COMPANY SNAPSHOT

21.10.2 REVENUE ANALYSIS

21.10.3 COMPANY SHARE ANALYSIS

21.10.4 PRODUCT PORTFOLIO

21.10.5 RECENT DEVELOPMENT

21.11 HANMI PHARM. CO., LTD.

21.11.1 COMPANY SNAPSHOT

21.11.2 REVENUE ANALYSIS

21.11.3 PRODUCT PORTFOLIO

21.11.4 RECENT DEVELOPMENT

21.12 MCNEIL CONSUMER PHARMACEUTICALS CO. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)

21.12.1 COMPANY SNAPSHOT

21.12.2 REVENUE ANALYSIS

21.12.3 PRODUCT PORTFOLIO

21.12.4 RECENT DEVELOPMENT

21.13 OTSUKA PHARMACEUTICAL CO., LTD.

21.13.1 COMPANY SNAPSHOT

21.13.2 REVENUE ANALYSIS

21.13.3 PRODUCT PORTFOLIO

21.13.4 RECENT DEVELOPMENT

21.14 PERRIGO COMPANY PLC

21.14.1 COMPANY SNAPSHOT

21.14.2 REVENUE ANALYSIS

21.14.3 PRODUCT PORTFOLIO

21.14.4 RECENT DEVELOPMENT

21.15 PRESTIGE CONSUMER HEALTHCARE, INC.

21.15.1 COMPANY SNAPSHOT

21.15.2 REVENUE ANALYSIS

21.15.3 PRODUCT PORTFOLIO

21.15.4 RECENT DEVELOPMENT

21.16 PROCTER & GAMBLE

21.16.1 COMPANY SNAPSHOT

21.16.2 REVENUE ANALYSIS

21.16.3 PRODUCT PORTFOLIO

21.16.4 RECENT DEVELOPMENT

21.17 RECKITT BENCKISER.

21.17.1 COMPANY SNAPSHOT

21.17.2 REVENUE ANALYSIS

21.17.3 PRODUCT PORTFOLIO

21.17.4 RECENT DEVELOPMENT

21.18 REDHILL BIOPHARMA LTD

21.18.1 COMPANY SNAPSHOT

21.18.2 REVENUE ANALYSIS

21.18.3 PRODUCT PORTFOLIO

21.18.4 RECENT DEVELOPMENT

21.19 SALIX PHARMACEUTICALS OR ITS AFFILIATES (SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.)

21.19.1 COMPANY SNAPSHOT

21.19.2 REVENUE ANALYSIS

21.19.3 PRODUCT PORTFOLIO

21.19.4 RECENT DEVELOPMENT

21.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED

21.20.1 COMPANY SNAPSHOT

21.20.2 REVENUE ANALYSIS

21.20.3 PRODUCT PORTFOLIO

21.20.4 RECENT DEVELOPMENTS

21.21 WOODWARD PHARMA

21.21.1 COMPANY SNAPSHOT

21.21.2 PRODUCT PORTFOLIO

21.21.3 RECENT DEVELOPMENT

21.22 ZERIA PHARMACEUTICAL CO., LTD.

21.22.1 COMPANY SNAPSHOT

21.22.2 REVENUE ANALYSIS

21.22.3 PRODUCT PORTFOLIO

21.22.4 RECENT DEVELOPMENT

22 QUESTIONNAIRE

23 RELATED REPORTS

表のリスト

TABLE 1 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 2 ASIA-PACIFIC NON-ULCER DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 3 ASIA-PACIFIC ORGANIC DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 4 ASIA-PACIFIC DRUG INDUCED DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 5 ASIA-PACIFIC OTHERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 6 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 7 ASIA-PACIFIC MEDICATION IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 8 ASIA-PACIFIC MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 9 ASIA-PACIFIC DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 10 ASIA-PACIFIC ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 11 ASIA-PACIFIC PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 12 ASIA-PACIFIC H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 13 ASIA-PACIFIC GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 14 ASIA-PACIFIC ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 15 ASIA-PACIFIC NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 16 ASIA-PACIFIC PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 17 ASIA-PACIFIC SURGERY IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 18 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 19 ASIA-PACIFIC GENERIC IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 20 ASIA-PACIFIC BRANDED IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 21 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 22 ASIA-PACIFIC WITHOUT PRESCRIPTION DRUGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 23 ASIA-PACIFIC PRESCRIPTION DRUGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 24 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 25 ASIA-PACIFIC ORAL IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 26 ASIA-PACIFIC ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 27 ASIA-PACIFIC INJECTABLE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 28 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 29 ASIA-PACIFIC FEMALE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 30 ASIA-PACIFIC FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 31 ASIA-PACIFIC MALE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 32 ASIA-PACIFIC MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 33 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 34 ASIA-PACIFIC HOSPITALS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 35 ASIA-PACIFIC HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 36 ASIA-PACIFIC HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 37 ASIA-PACIFIC CLINICS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 38 ASIA-PACIFIC HOMECARE SETTINGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 39 ASIA-PACIFIC SPECIALTY CLINICS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 40 ASIA-PACIFIC AMBULATORY CENTERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 41 ASIA-PACIFIC ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 42 ASIA-PACIFIC OTHERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 43 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 44 ASIA-PACIFIC RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 45 ASIA-PACIFIC RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 46 ASIA-PACIFIC DIRECT TENDER IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 47 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 48 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 49 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 50 ASIA-PACIFIC MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 51 ASIA-PACIFIC DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 52 ASIA-PACIFIC ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 53 ASIA-PACIFIC PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 54 ASIA-PACIFIC PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 55 ASIA-PACIFIC H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030, (USD THOUSANDS )

TABLE 56 ASIA-PACIFIC H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 57 ASIA-PACIFIC GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 58 ASIA-PACIFIC GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 59 ASIA-PACIFIC ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 60 ASIA-PACIFIC ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 61 ASIA-PACIFIC NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 62 ASIA-PACIFIC PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 63 ASIA-PACIFIC PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 64 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 65 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 66 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 67 ASIA-PACIFIC ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 68 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 69 ASIA-PACIFIC FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 70 ASIA-PACIFIC MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 71 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 72 ASIA-PACIFIC HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 73 ASIA-PACIFIC HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 74 ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 75 ASIA-PACIFIC RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 76 JAPAN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 77 JAPAN DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 78 JAPAN MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 79 JAPAN DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 80 JAPAN ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 81 JAPAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 82 JAPAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 83 JAPAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 84 JAPAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 85 JAPAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 86 JAPAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 87 JAPAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 88 JAPAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 89 JAPAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 90 JAPAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 91 JAPAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 92 JAPAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 93 JAPAN NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 94 JAPAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 95 JAPAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 96 JAPAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 97 JAPAN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 98 JAPAN DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 99 JAPAN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 100 JAPAN ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 101 JAPAN DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 102 JAPAN FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 103 JAPAN MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 104 JAPAN DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 105 JAPAN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 106 JAPAN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 107 JAPAN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 108 JAPAN RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 109 .CHINA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 110 CHINA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 111 CHINA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 112 CHINA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 113 CHINA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 114 CHINA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 115 CHINA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 116 CHINA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 117 CHINA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 118 CHINA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 119 CHINA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 120 CHINA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 121 CHINA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 122 CHINA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 123 CHINA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 124 CHINA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 125 CHINA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 126 CHINA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 127 CHINA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 128 CHINA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 129 CHINA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 130 CHINA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 131 CHINA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 132 CHINA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 133 CHINA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 134 CHINA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 135 CHINA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 136 CHINA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 137 CHINA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 138 CHINA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 139 CHINA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 140 CHINA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 141 CHINA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 142 SOUTH KOREA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 143 SOUTH KOREA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 144 SOUTH KOREA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 145 SOUTH KOREA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 146 SOUTH KOREA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 147 SOUTH KOREA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 148 SOUTH KOREA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 149 SOUTH KOREA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 150 SOUTH KOREA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 151 SOUTH KOREA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 152 SOUTH KOREA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 153 SOUTH KOREA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 154 SOUTH KOREA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 155 SOUTH KOREA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 156 SOUTH KOREA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 157 SOUTH KOREA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 158 SOUTH KOREA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 159 SOUTH KOREA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 160 SOUTH KOREA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 161 SOUTH KOREA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 162 SOUTH KOREA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 163 SOUTH KOREA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 164 SOUTH KOREA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 165 SOUTH KOREA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 166 SOUTH KOREA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 167 SOUTH KOREA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 168 SOUTH KOREA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 169 SOUTH KOREA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 170 SOUTH KOREA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 171 SOUTH KOREA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 172 SOUTH KOREA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 173 SOUTH KOREA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 174 SOUTH KOREA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 175 INDIA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 176 INDIA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 177 INDIA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 178 INDIA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 179 INDIA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 180 INDIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 181 INDIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 182 INDIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 183 INDIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 184 INDIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 185 INDIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 186 INDIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 187 INDIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 188 INDIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 189 INDIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 190 INDIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 191 INDIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 192 INDIA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 193 INDIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 194 INDIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 195 INDIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 196 INDIA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 197 INDIA BRANDED IN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 198 INDIA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 199 INDIA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 200 INDIA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 201 INDIA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 202 INDIA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 203 INDIA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 204 INDIA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 205 INDIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 206 INDIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 207 INDIA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 208 INDIA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 209 AUSTRALIA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 210 AUSTRALIA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 211 AUSTRALIA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 212 AUSTRALIA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 213 AUSTRALIA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 214 AUSTRALIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 215 AUSTRALIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 216 AUSTRALIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 217 AUSTRALIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 218 AUSTRALIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 219 AUSTRALIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 220 AUSTRALIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 221 AUSTRALIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 222 AUSTRALIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 223 AUSTRALIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 224 AUSTRALIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 225 AUSTRALIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 226 AUSTRALIA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 227 AUSTRALIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 228 AUSTRALIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 229 AUSTRALIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 230 AUSTRALIA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 231 AUSTRALIA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 232 AUSTRALIA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 233 AUSTRALIA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 234 AUSTRALIA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 235 AUSTRALIA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 236 AUSTRALIA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 237 AUSTRALIA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 238 AUSTRALIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 239 AUSTRALIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 240 AUSTRALIA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 241 AUSTRALIA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 242 NEW ZEALAND DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 243 NEW ZEALAND DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 244 NEW ZEALAND MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 245 NEW ZEALAND DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 246 NEW ZEALAND ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 247 NEW ZEALAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 248 NEW ZEALAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 249 NEW ZEALAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 250 NEW ZEALAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 251 NEW ZEALAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 252 NEW ZEALAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 253 NEW ZEALAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 254 NEW ZEALAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 255 NEW ZEALAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 256 NEW ZEALAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 257 NEW ZEALAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 258 NEW ZEALAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 259 NEW ZEALAND NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 260 NEW ZEALAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 261 NEW ZEALAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 262 NEW ZEALAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 263 NEW ZEALAND DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 264 NEW ZEALAND DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 265 NEW ZEALAND DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 266 NEW ZEALAND ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 267 NEW ZEALAND DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 268 NEW ZEALAND FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 269 NEW ZEALAND MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 270 NEW ZEALAND DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 271 NEW ZEALAND HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 272 NEW ZEALAND HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 273 NEW ZEALAND DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 274 NEW ZEALAND RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 275 SINGAPORE DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 276 SINGAPORE DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 277 SINGAPORE MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 278 SINGAPORE DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 279 SINGAPORE ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 280 SINGAPORE PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 281 SINGAPORE PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 282 SINGAPORE PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 283 SINGAPORE H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 284 SINGAPORE H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 285 SINGAPORE H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 286 SINGAPORE GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 287 SINGAPORE GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 288 SINGAPORE GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 289 SINGAPORE ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 290 SINGAPORE ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 291 SINGAPORE ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 292 SINGAPORE NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 293 SINGAPORE PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 294 SINGAPORE PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 295 SINGAPORE PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 296 SINGAPORE DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 297 SINGAPORE DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 298 SINGAPORE DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 299 SINGAPORE ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 300 SINGAPORE DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 301 SINGAPORE FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 302 SINGAPORE MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 303 SINGAPORE DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 304 SINGAPORE HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 305 SINGAPORE HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 306 SINGAPORE DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 307 SINGAPORE RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 308 THAILAND DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 309 THAILAND DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 310 THAILAND MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 311 THAILAND DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 312 THAILAND ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 313 THAILAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 314 THAILAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 315 THAILAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 316 THAILAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 317 THAILAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 318 THAILAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 319 THAILAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 320 THAILAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 321 THAILAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 322 THAILAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 323 THAILAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 324 THAILAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 325 THAILAND NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 326 THAILAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 327 THAILAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 328 THAILAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 329 THAILAND DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 330 THAILAND DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 331 THAILAND DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 332 THAILAND ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 333 THAILAND DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 334 THAILAND FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 335 THAILAND MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 336 THAILAND DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 337 THAILAND HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 338 THAILAND HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 339 THAILAND DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 340 THAILAND RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 341 INDONESIA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 342 INDONESIA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 343 INDONESIA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 344 INDONESIA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 345 INDONESIA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 346 INDONESIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 347 INDONESIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 348 INDONESIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 349 INDONESIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 350 INDONESIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 351 INDONESIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 352 INDONESIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 353 INDONESIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 354 INDONESIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 355 INDONESIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 356 INDONESIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 357 INDONESIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 358 INDONESIA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 359 INDONESIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 360 INDONESIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 361 INDONESIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 362 INDONESIA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 363 INDONESIA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 364 INDONESIA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 365 INDONESIA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 366 INDONESIA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 367 INDONESIA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 368 INDONESIA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 369 INDONESIA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 370 INDONESIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 371 INDONESIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 372 INDONESIA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 373 INDONESIA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 374 MALAYSIA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 375 MALAYSIA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 376 MALAYSIA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 377 MALAYSIA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 378 MALAYSIA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 379 MALAYSIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 380 MALAYSIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 381 MALAYSIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 382 MALAYSIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 383 MALAYSIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 384 MALAYSIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 385 MALAYSIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 386 MALAYSIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 387 MALAYSIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 388 MALAYSIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 389 MALAYSIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 390 MALAYSIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 391 MALAYSIA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 392 MALAYSIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 393 MALAYSIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 394 MALAYSIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 395 MALAYSIA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 396 MALAYSIA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 397 MALAYSIA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 398 MALAYSIA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 399 MALAYSIA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 400 MALAYSIA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 401 MALAYSIA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 402 MALAYSIA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 403 MALAYSIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 404 MALAYSIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 405 MALAYSIA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 406 MALAYSIA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 407 PHILIPPINES DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 408 PHILIPPINES DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 409 PHILIPPINES MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 410 PHILIPPINES DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 411 PHILIPPINES ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 412 PHILIPPINES PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 413 PHILIPPINES PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 414 PHILIPPINES PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 415 PHILIPPINES H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 416 PHILIPPINES H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 417 PHILIPPINES H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 418 PHILIPPINES GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 419 PHILIPPINES GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 420 PHILIPPINES GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 421 PHILIPPINES ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 422 PHILIPPINES ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 423 PHILIPPINES ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 424 PHILIPPINES NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 425 PHILIPPINES PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 426 PHILIPPINES PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 427 PHILIPPINES PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 428 PHILIPPINES DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 429 PHILIPPINES DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 430 PHILIPPINES DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 431 PHILIPPINES ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 432 PHILIPPINES DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 433 PHILIPPINES FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 434 PHILIPPINES MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 435 PHILIPPINES DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 436 PHILIPPINES HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 437 PHILIPPINES HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 438 PHILIPPINES DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 439 PHILIPPINES RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 440 VIETNAM DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 441 VIETNAM DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 442 VIETNAM MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 443 VIETNAM DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 444 VIETNAM ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 445 VIETNAM PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 446 VIETNAM PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 447 VIETNAM PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 448 VIETNAM H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 449 VIETNAM H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 450 VIETNAM H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 451 VIETNAM GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 452 VIETNAM GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 453 VIETNAM GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 454 VIETNAM ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 455 VIETNAM ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 456 VIETNAM ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 457 VIETNAM NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 458 VIETNAM PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 459 VIETNAM PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 460 VIETNAM PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 461 VIETNAM DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 462 VIETNAM DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 463 VIETNAM DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 464 VIETNAM ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 465 VIETNAM DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 466 VIETNAM FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 467 VIETNAM MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 468 VIETNAM DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 469 VIETNAM HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 470 VIETNAM HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 471 VIETNAM DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 472 VIETNAM RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 473 TAIWAN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 474 TAIWAN DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 475 TAIWAN MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 476 TAIWAN DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 477 TAIWAN ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 478 TAIWAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 479 TAIWAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 480 TAIWAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 481 TAIWAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 482 TAIWAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 483 TAIWAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 484 TAIWAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 485 TAIWAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 486 TAIWAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 487 TAIWAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 488 TAIWAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 489 TAIWAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 490 TAIWAN NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 491 TAIWAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 492 TAIWAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 493 TAIWAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 494 TAIWAN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 495 TAIWAN DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 496 TAIWAN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 497 TAIWAN ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 498 TAIWAN DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 499 TAIWAN FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 500 TAIWAN MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 501 TAIWAN DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 502 TAIWAN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 503 TAIWAN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 504 TAIWAN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 505 TAIWAN RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 506 REST OF ASIA-PACIFIC DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

図表一覧

FIGURE 1 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: SEGMENTATION

FIGURE 2 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: DATA TRIANGULATION

FIGURE 3 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: DROC ANALYSIS

FIGURE 4 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: ASIA-PACIFIC VS. REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: MULTIVARIATE MODELLING

FIGURE 8 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: DBMR MARKET POSITION GRID

FIGURE 9 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: MARKET END-USER COVERAGE GRID

FIGURE 11 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: SEGMENTATION

FIGURE 12 INCREASE IN THE PREVALENCE OF METABOLIC DISORDERS IS EXPECTED TO DRIVE THE ASIA-PACIFIC DYSPEPSIA DRUG MARKET GROWTH IN THE FORECAST PERIOD FROM 2023 TO 2030

FIGURE 13 NON-ULCER DYSPEPSIA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC DYSPEPSIA DRUG MARKET IN 2023 & 2030

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA-PACIFIC DYSPEPSIA DRUG MARKET

FIGURE 15 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TYPE, 2022

FIGURE 16 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TYPE, 2023-2030 (USD THOUSAND)

FIGURE 17 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 18 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TYPE, LIFELINE CURVE

FIGURE 19 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , 2022

FIGURE 20 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND)

FIGURE 21 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , CAGR (2023-2030)

FIGURE 22 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , LIFELINE CURVE

FIGURE 23 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY DRUG TYPE, 2022

FIGURE 24 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY DRUG TYPE, 2023-2030 (USD THOUSAND)

FIGURE 25 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY DRUG TYPE, CAGR (2023-2030)

FIGURE 26 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 27 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, 2022

FIGURE 28 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, 2023-2030 (USD THOUSAND)

FIGURE 29 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, CAGR (2023-2030)

FIGURE 30 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, LIFELINE CURVE

FIGURE 31 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2022

FIGURE 32 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND)

FIGURE 33 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)

FIGURE 34 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 35 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY GENDER, 2022

FIGURE 36 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY GENDER, 2023-2030 (USD THOUSAND)

FIGURE 37 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY GENDER, CAGR (2023-2030)

FIGURE 38 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY GENDER, LIFELINE CURVE

FIGURE 39 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY END USER, 2022

FIGURE 40 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY END USER, 2023-2030 (USD THOUSAND)

FIGURE 41 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY END USER, CAGR (2023-2030)

FIGURE 42 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY END USER, LIFELINE CURVE

FIGURE 43 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 44 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)

FIGURE 45 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 46 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 47 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: SNAPSHOT (2022)

FIGURE 48 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY COUNTRY (2022)

FIGURE 49 ASIA-PACIFIC DYSPEPSIA DRUG DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 50 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY COUNTRY (2022 & 2030)

FIGURE 51 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: BY TYPE (2023-2030)

FIGURE 52 ASIA-PACIFIC DYSPEPSIA DRUG MARKET: COMPANY SHARE 2022 (%)

詳細情報を見る Right Arrow

調査方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。

Frequently Asked Questions

The Asia-Pacific Dyspepsia Drug Market is projected to grow at a CAGR of 6.1% during the forecast period by 2030.
The future market value of the Asia-Pacific Dyspepsia Drug Market is expected to reach USD 96.81 million by 2030.
The major players in the Asia-Pacific Dyspepsia Drug Market are Bayer AG, Cadila Pharmaceuticals., Sanofi, Lupin., Abbott., Perrigo Company plc, AstraZeneca, Procter & Gamble, and Reckitt Benckiser among others.
The countries covered in the Asia-Pacific Dyspepsia Drug Market are Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, New Zealand, Vietnam, Taiwan, and Rest of Asia-Pacific.
a